AU2020387478A8 - Kit for preparing nanoparticle composition for drug delivery - Google Patents
Kit for preparing nanoparticle composition for drug delivery Download PDFInfo
- Publication number
- AU2020387478A8 AU2020387478A8 AU2020387478A AU2020387478A AU2020387478A8 AU 2020387478 A8 AU2020387478 A8 AU 2020387478A8 AU 2020387478 A AU2020387478 A AU 2020387478A AU 2020387478 A AU2020387478 A AU 2020387478A AU 2020387478 A8 AU2020387478 A8 AU 2020387478A8
- Authority
- AU
- Australia
- Prior art keywords
- kit
- drug delivery
- nanoparticle composition
- preparing
- preparing nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
The present invention relates to a kit for preparing a nanoparticle composition for drug delivery and, more specifically, to a kit for preparing a nanoparticle composition for drug delivery, wherein the kit is designed such that the kit does not comprise a polylactic acid salt and nanoparticles containing a drug encapsulated therein can be easily formed just by simply mixing an amphiphilic block copolymer, a cationic compound, and a drug as components of the kit.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190151227 | 2019-11-22 | ||
KR10-2019-0151227 | 2019-11-22 | ||
PCT/KR2020/016359 WO2021101265A1 (en) | 2019-11-22 | 2020-11-19 | Kit for preparing nanoparticle composition for drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2020387478A1 AU2020387478A1 (en) | 2022-06-16 |
AU2020387478A8 true AU2020387478A8 (en) | 2022-06-30 |
Family
ID=75980970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020387478A Pending AU2020387478A1 (en) | 2019-11-22 | 2020-11-19 | Kit for preparing nanoparticle composition for drug delivery |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230017360A1 (en) |
EP (1) | EP4062908A4 (en) |
JP (1) | JP2023503910A (en) |
KR (1) | KR102607199B1 (en) |
CN (1) | CN114980870A (en) |
AU (1) | AU2020387478A1 (en) |
BR (1) | BR112022009773A2 (en) |
CA (1) | CA3159021A1 (en) |
WO (1) | WO2021101265A1 (en) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2958076B2 (en) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
TW203552B (en) * | 1992-02-18 | 1993-04-11 | J Baroody Lloyd | Compositions of clindamycin and benzoyl peroxide for acne treatment |
JP4335310B2 (en) * | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Lipid-nucleic acid particles prepared through hydrophobic lipid-nucleic acid complex intermediates and use for gene transfer |
BR9702049B1 (en) * | 1996-01-31 | 2010-08-10 | dispensing system containing two compartments for simultaneous dosing of two aqueous compositions. | |
US6235310B1 (en) * | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
DE10040610A1 (en) * | 2000-08-16 | 2002-03-07 | Schwabe Willmar Gmbh & Co | Flavonhaltige plant extract solutions with improved storage and heat stability |
US10292932B2 (en) * | 2008-12-26 | 2019-05-21 | Samyang Biopharmaceuticals Corporation | Polymeric micelle particle comprising anionic drugs and method of preparing the same |
EP2833869B1 (en) * | 2012-04-04 | 2020-10-28 | Samyang Biopharmaceuticals Corporation | Method of preparing composition for delivering an anionic drug |
KR101507119B1 (en) * | 2013-05-31 | 2015-03-30 | 주식회사 바이오리더스 | Mucoadhesive Poly-γ-glutamic acid Nanomicelles and Drug Delivery Vector Use thereof |
AU2016324450B2 (en) * | 2015-09-15 | 2019-04-18 | Samyang Holdings Corporation | Pharmaceutical composition containing anionic drug, and preparation method therefor |
NZ743320A (en) * | 2015-12-18 | 2019-03-29 | Samyang Biopharmaceuticals | Method for preparing polymeric micelle containing anionic drug |
KR20190127277A (en) * | 2018-05-04 | 2019-11-13 | 주식회사 삼양바이오팜 | Polymeric nanoparticle composition for delivering mRNA and preparation method thereof |
-
2020
- 2020-11-19 WO PCT/KR2020/016359 patent/WO2021101265A1/en active Application Filing
- 2020-11-19 KR KR1020200155276A patent/KR102607199B1/en active IP Right Grant
- 2020-11-19 CA CA3159021A patent/CA3159021A1/en active Pending
- 2020-11-19 BR BR112022009773A patent/BR112022009773A2/en unknown
- 2020-11-19 CN CN202080092844.7A patent/CN114980870A/en active Pending
- 2020-11-19 AU AU2020387478A patent/AU2020387478A1/en active Pending
- 2020-11-19 JP JP2022529716A patent/JP2023503910A/en active Pending
- 2020-11-19 US US17/778,655 patent/US20230017360A1/en active Pending
- 2020-11-19 EP EP20891247.7A patent/EP4062908A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102607199B1 (en) | 2023-11-29 |
EP4062908A4 (en) | 2024-01-24 |
KR20210064072A (en) | 2021-06-02 |
BR112022009773A2 (en) | 2022-08-09 |
EP4062908A1 (en) | 2022-09-28 |
CA3159021A1 (en) | 2021-05-27 |
CN114980870A (en) | 2022-08-30 |
US20230017360A1 (en) | 2023-01-19 |
JP2023503910A (en) | 2023-02-01 |
WO2021101265A1 (en) | 2021-05-27 |
AU2020387478A1 (en) | 2022-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196413A (en) | Substituted Carbonucleoside Derivatives Useful as Anticancer Agents | |
WO2013179307A3 (en) | Stabilized pharmaceutical compositions of saxagliptin | |
NZ743320A (en) | Method for preparing polymeric micelle containing anionic drug | |
WO2017218981A3 (en) | Compositions and methods for reducing ocular neovascularization | |
MX2019006221A (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery. | |
MX2019011094A (en) | Adhesive composition and method for preparing same. | |
MX2018006486A (en) | Oral care compositions. | |
MX2018003096A (en) | Pharmaceutical composition containing anionic drug, and preparation method therefor. | |
WO2013089394A3 (en) | Composition of an aqueous solution of polymeric nanoparticles and method for preparing same | |
MX2018009500A (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms. | |
CA2920410C (en) | Thienopiperidine derivative and use thereof | |
MX2018014576A (en) | Drug-delivery nanoparticles and treatments for drug-resistant cancer. | |
MY189448A (en) | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
MY173159A (en) | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer | |
MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
BR112022012118A2 (en) | KIT TO PREPARE A NANOPARTICLES COMPOSITION | |
AU2020387478A8 (en) | Kit for preparing nanoparticle composition for drug delivery | |
MX2016015660A (en) | Composition based on a stabilized solution of active ingredients. | |
WO2017134463A3 (en) | Method of preparing an oxidatively curable coating formulation | |
EA202091561A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE LENALIDOMIDE SALT | |
WO2016195194A3 (en) | Novel tlr2 antagonists | |
MX2020006830A (en) | Amphiphilic copolymers as surface modifiers for production of improved calcium carbonate powders. | |
CN104222105A (en) | Compound preservative containing dimethyl 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione and preparation method thereof | |
PH12017550051A1 (en) | A pharmaceutical composition for treating gastrointestinal diseases | |
AU2017251957A1 (en) | Hyaluronic acid conjugates and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH | Corrigenda |
Free format text: IN VOL 36 , NO 24 , PAGE(S) 3422 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SAMYANG BIOPHARMACEUTICALS CORPORATION, APPLICATION NO. 2020387478, UNDER INID (71) CORRECT THE APPLICANT NAME TO SAMYANG HOLDINGS CORPORATION |